Dr Reddys Lab

Cash Trade | Price for Dr Reddy's Lab is breaking out of downsloping wedge pattern

Dr Reddy's Lab price crosses above the 50-day moving average, and MACD gives a buy signal

Dr Reddy's Lab recalls over 4,000 bottles of generic drug in US

The Hyderabad-based drug major is recalling 4,320 bottles of Tacrolimus Capsules which are used to prevent the body from rejecting a transplanted organ.

Indian pharmaceutical industry to touch $130 billion by 2030: Dr Reddy's chairman K Satish Reddy

Dr Reddy's Laboratories' chairman was of the opinion that the Indian pharma industry needs to develop stronger capabilities in innovation and R&D. Despite have the capabilities, Indian pharma industry do not get much global attention, he added.

Dr Reddy's signs licensing pact with Eli Lilly to produce COVID-19 treatment drug Baricitinib

The Hyderabad-based company has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly for the manufacture and marketing of the drug in India.

Dr Reddy’s Lab Q4 PAT may dip 13.6% YoY to Rs. 674.5 cr: Sharekhan

Net Sales are expected to increase by 9 percent Y-o-Y (down 1.9 percent Q-o-Q) to Rs. 4,849.3 crore, according to Sharekhan.

Dr. Reddy’s Lab Q3 PAT to Rs. 729.7 cr: Yash Securities

Net Sales are expected to increase by 16.5 percent Y-o-Y (up 4.3 percent Q-o-Q) to Rs. 5,121.8 crore, according to Yash Securities.

Dr Reddy's Lab shares fall 4% after firm shuts plants on reports of data breach

The company’s plants in India, Brazil, Russia, the United Kingdom and the United States were impacted by the breach which happened between 4.00-5.00 pm (US time), the report suggests.

Hold Dr. Reddy's Lab; target of Rs 5325: Emkay Global Financial

Emkay Global Financial recommended hold rating on Dr. Reddy's Lab with a target price of Rs 5325 in its research report dated September 17, 2020.

Divi’s Labs an outlier in the pharma sector

Divi’s Lab is now reaping the benefits of its strategic vision

5 reasons why Nomura downgraded Indian equities to ‘neutral’

Top stocks from Nomura include ICICI Bank, Axis Bank, Larsen & Toubro and Dr. Reddy's Lab.

Dr. Reddy’s Lab Q3 PAT seen up 60.6% YoY to Rs. 472.4 cr: Sharekhan

Net Sales are expected to increase by 1.9 percent Y-o-Y (up 2.3 percent Q-o-Q) to Rs. 3,905 crore, according to Sharekhan.

Dr. Reddy’s Lab Q2 PAT seen up 20.2% YoY to Rs. 356.1 cr: Sharekhan

Net Sales are expected to increase by 5.3 percent Y-o-Y (up 0.4 percent Q-o-Q) to Rs. 3,750 crore, according to Sharekhan.

Automobile, pharma firms big beneficiaries of export incentive scheme

Under the Merchandise Exports from India Scheme (MEIS), the government provides duty benefits at different rates depending on product and country.

Hold Dr Reddy's Lab; target of Rs 2000: Centrum Research

Centrum Research recommended hold rating on Dr Reddy's Lab with a target price of Rs 2000 in its research report dated May 28, 2018.

Dr. Reddy’s Lab Q4 PAT may dip 17.7% YoY to Rs. 269.4 cr: KR Choksey

Net Sales are expected to increase by 11.1 percent Y-o-Y (down 3.7 percent Q-o-Q) to Rs. 3,663.7 crore, according to KR Choksey.

India Inc pay gap: CEOs earn up to 1,200-times of average staff

An analysis of remuneration disclosures made by top listed companies forming part of the blue-chip index Sensex -- under directions of the capital markets regulator Sebi -- shows that the pay packages of senior-most personnel such as CEOs and executive chairmen continue to remain high and rose further at most private sector firms during 2016-17.